Related Experiment Video
Updated: Jun 26, 2026

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression
Christian Wider1, Justus C Dachsel, Alexandra I Soto
1Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA. wider.christian@mayo.edu
Abstract:
Genetic variation in fibroblast growth factor 20 (FGF20) has been associated with risk of Parkinson's disease (PD). Functional evidence suggested the T allele of one SNP, rs12720208 C/T, altered PD risk by increasing FGF20 and alpha-synuclein protein levels. Herein we report our association study of FGF20 and PD risk in four patient-control series (total: 1,262 patients and 1,881 controls), and measurements of FGF20 and alpha-synuclein protein levels in brain samples (nine patients). We found no evidence of association between FGF20 variability and PD risk, and no relationship between the rs12720208 genotype, FGF20 and alpha-synuclein protein levels.
More Related Videos
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation
Alzheimer Disease ll: Pathophysiology

